Tokyo, July 18 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058463) titled 'Evaluation of Post-Treatment Benefits of Formulation Use Containing Active Ingredient of Quasi-drug Following Pico Laser Toning for Melasma' on July 18.
Study Type:
Interventional
Study Design:
Basic Design - Parallel
Randomization - Randomized
Blinding - Double blind -all involved are blinded
Control - Placebo
Primary Sponsor:
Institute - POLA Chemical Industries, Inc.
Condition:
Condition - Melasma
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - Safety Assessment
The incidence of adverse effects will be compared between the application sites of the formulation ...